RHOBTB1

Summary

RHOBTB1 (Rho related BTB domain containing 1, HGNC:18738) is a protein-coding gene on chromosome 10q21.2, encoding Rho-related BTB domain-containing protein 1 (O94844).

The protein encoded by this gene belongs to the Rho family of the small GTPase superfamily. It contains a GTPase domain, a proline-rich region, a tandem of 2 BTB (broad complex, tramtrack, and bric-a-brac) domains, and a conserved C-terminal region. The protein plays a role in small GTPase-mediated signal transduction and the organization of the actin filament system. Alternate splicing results in multiple transcript variants.

Source: NCBI Gene 9886 — RefSeq curated summary.

At a glance

• GWAS associations: 7
• Clinical variants (ClinVar): 89 total
• MANE Select transcript: NM_014836

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:18738
Approved symbol	RHOBTB1
Name	Rho related BTB domain containing 1
Location	10q21.2
Locus type	gene with protein product
Status	Approved
Aliases	KIAA0740
Ensembl gene	ENSG00000072422
Ensembl biotype	protein_coding
OMIM	607351
Entrez	9886

Gene structure

Transcript identifiers

Ensembl transcripts: 25 — 21 protein_coding, 4 protein_coding_CDS_not_defined

ENST00000337910, ENST00000357917, ENST00000461910, ENST00000483488, ENST00000490827, ENST00000496237, ENST00000864402, ENST00000864403, ENST00000864404, ENST00000864405, ENST00000864406, ENST00000864407, ENST00000864408, ENST00000864409, ENST00000864410, ENST00000864411, ENST00000924652, ENST00000924653, ENST00000924654, ENST00000948403, ENST00000948404, ENST00000948405, ENST00000948406, ENST00000948407, ENST00000948408

RefSeq mRNA: 12 — MANE Select: NM_014836 NM_001242359, NM_001350902, NM_001350903, NM_001350904, NM_001350905, NM_001350906, NM_001350907, NM_001350908, NM_001350909, NM_001350910, NM_001350911, NM_014836

CCDS: CCDS7261

Canonical transcript exons

ENST00000337910 — 11 exons

Exon	Start	End
ENSE00000705848	60886112	60886230
ENSE00000705880	60892810	60892995
ENSE00000705883	60910887	60910990
ENSE00000985929	60888212	60889185
ENSE00000985930	60874954	60875042
ENSE00000985931	60872185	60872290
ENSE00001173242	60941804	60941854
ENSE00001173247	60943971	60944185
ENSE00001461607	60869438	60871651
ENSE00001461616	60911351	60911552
ENSE00003693723	60877908	60878058

Expression profiles

Bgee: expression breadth ubiquitous, 279 present calls, max score 97.75.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 6.2030 / max 96.3514, expressed in 1413 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter ID	TPM avg	Samples expressed
109558	3.3958	1217
109557	1.2094	702
109560	0.5947	335
109563	0.4642	124
109561	0.3416	148
109559	0.1270	35
109562	0.0704	41

Top tissues by expression

292 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
vastus lateralis	UBERON:0001379	97.75	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	97.57	gold quality
quadriceps femoris	UBERON:0001377	97.18	gold quality
calcaneal tendon	UBERON:0003701	97.12	gold quality
hindlimb stylopod muscle	UBERON:0004252	96.98	gold quality
right uterine tube	UBERON:0001302	96.09	gold quality
biceps brachii	UBERON:0001507	96.09	gold quality
skeletal muscle tissue	UBERON:0001134	95.73	gold quality
placenta	UBERON:0001987	95.65	gold quality
muscle organ	UBERON:0001630	95.56	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	95.49	gold quality
muscle of leg	UBERON:0001383	95.16	gold quality
cardia of stomach	UBERON:0001162	95.08	gold quality
gluteal muscle	UBERON:0002000	94.99	gold quality
triceps brachii	UBERON:0001509	94.71	gold quality
gastrocnemius	UBERON:0001388	94.67	gold quality
diaphragm	UBERON:0001103	94.25	gold quality
adrenal tissue	UBERON:0018303	94.10	gold quality
pylorus	UBERON:0001166	93.37	gold quality
muscle tissue	UBERON:0002385	93.35	gold quality
fundus of stomach	UBERON:0001160	93.02	gold quality
deltoid	UBERON:0001476	92.68	gold quality
body of stomach	UBERON:0001161	92.55	gold quality
right testis	UBERON:0004534	92.04	gold quality
stomach	UBERON:0000945	91.92	gold quality
left testis	UBERON:0004533	91.80	gold quality
tibia	UBERON:0000979	91.79	gold quality
nephron tubule	UBERON:0001231	91.68	gold quality
right coronary artery	UBERON:0001625	91.47	gold quality
testis	UBERON:0000473	91.09	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-CURD-119	yes	48.63
E-ANND-3	yes	6.36
E-GEOD-137537	yes	6.35

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

208 targeting RHOBTB1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-29A-3P	100.00	73.11	1835
HSA-MIR-29B-3P	100.00	73.18	1833
HSA-MIR-29C-3P	100.00	73.15	1833
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-4673	100.00	66.64	1490
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-6077	99.99	68.04	2299
HSA-MIR-1184	99.99	68.19	1458
HSA-MIR-568	99.98	69.86	2084
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-559	99.95	72.28	3609
HSA-MIR-96-5P	99.95	72.80	2140

Literature-anchored findings (GeneRIF, showing 6)

• Frequent allelic loss and decreased expression of RHOBTB1 suggested that this gene has a role in tumorigenesis of a subset of HNSCC (Head-Neck Squamous Cell Carcinoma). (PMID:16170569)
• we found that miR-31 acts as an oncogene in colon cancer and identified RhoBTB1 as a new target of miR-31 further study demonstrated that miR-31 contributed to the development of colon cancer at least partly by targeting RhoBTB1. (PMID:23258531)
• RhoBTB1 regulates the integrity of the Golgi complex through METTL7B. RhoBTB1 is required for expression of METTL7B and silencing of either protein leads to fragmentation of the Golgi. Loss of RhoBTB1 expression is linked to Golgi fragmentation in breast cancer cells. Restoration of normal RhoBTB1 expression rescues Golgi morphology and dramatically inhibits breast cancer cell invasion. (PMID:28219369)
• RhoBTB1 associates with ROCK1 and ROCK2 and its association with ROCK1 is via its Rho domain. (PMID:31431478)
• RNA Interference Screening Identifies Novel Roles for RhoBTB1 and RhoBTB3 in Membrane Trafficking Events in Mammalian Cells. (PMID:32354068)
• Structure and Function of RhoBTB1 Required for Substrate Specificity and Cullin-3 Ubiquitination. (PMID:37575477)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	rhobtb1	ENSDARG00000079468
mus_musculus	Rhobtb1	ENSMUSG00000019944
rattus_norvegicus	Rhobtb1	ENSRNOG00000000633

Paralogs (22): RHOBTB2 (ENSG00000008853), RHOA (ENSG00000067560), CDC42 (ENSG00000070831), RHOV (ENSG00000104140), RND2 (ENSG00000108830), RND3 (ENSG00000115963), RHOU (ENSG00000116574), RHOQ (ENSG00000119729), RHOJ (ENSG00000126785), RHOT1 (ENSG00000126858), RAC2 (ENSG00000128340), RAC1 (ENSG00000136238), RHOF (ENSG00000139725), RHOT2 (ENSG00000140983), RHOB (ENSG00000143878), RHOC (ENSG00000155366), RHOBTB3 (ENSG00000164292), RHOH (ENSG00000168421), RAC3 (ENSG00000169750), RND1 (ENSG00000172602), RHOD (ENSG00000173156), RHOG (ENSG00000177105)

Protein

Protein identifiers

Rho-related BTB domain-containing protein 1 — O94844 (reviewed: O94844)

All UniProt accessions (1): O94844

UniProt curated annotations — full annotation on UniProt →

Tissue specificity. Ubiquitous, with highest levels in skeletal muscle, placenta, testis, stomach, and kidney, followed by uterus and adrenal gland. Expressed in a variety of fetal tissues.

Similarity. Belongs to the small GTPase superfamily. Rho family.

RefSeq proteins (12): NP_001229288, NP_001337831, NP_001337832, NP_001337833, NP_001337834, NP_001337835, NP_001337836, NP_001337837, NP_001337838, NP_001337839, NP_001337840, NP_055651* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000210	BTB/POZ_dom	Domain
IPR001806	Small_GTPase	Family
IPR003578	Small_GTPase_Rho	Family
IPR011333	SKP1/BTB/POZ_sf	Homologous_superfamily
IPR027417	P-loop_NTPase	Homologous_superfamily

Pfam: PF00071, PF00651

UniProt features (8 total): binding site 3, domain 2, region of interest 2, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O94844-F1	82.31	0.62

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (3): 21–28; 84–88; 140–143

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-9013422	RHOBTB1 GTPase cycle

MSigDB gene sets: 269 (showing top): TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_MONOCYTE_UP, AAGCAAT_MIR137, GOBP_REGULATION_OF_CELL_MORPHOGENESIS, GOBP_ESTABLISHMENT_OR_MAINTENANCE_OF_CELL_POLARITY, chr10q21, MEF2_02, TAL1ALPHAE47_01, GOBP_REGULATION_OF_ACTIN_FILAMENT_BASED_PROCESS, SENESE_HDAC1_AND_HDAC2_TARGETS_DN, GHO_ATF5_TARGETS_UP, PAX8_B, NKX62_Q2, SOX9_B1, GOBP_ACTIN_FILAMENT_ORGANIZATION, KINSEY_TARGETS_OF_EWSR1_FLII_FUSION_DN

GO Biological Process (7): actin filament organization (GO:0007015), establishment or maintenance of cell polarity (GO:0007163), signal transduction (GO:0007165), small GTPase-mediated signal transduction (GO:0007264), regulation of cell shape (GO:0008360), cortical cytoskeleton organization (GO:0030865), regulation of actin cytoskeleton organization (GO:0032956)

GO Molecular Function (5): GTPase activity (GO:0003924), GTP binding (GO:0005525), protein kinase binding (GO:0019901), nucleotide binding (GO:0000166), protein binding (GO:0005515)

GO Cellular Component (5): cytoskeleton (GO:0005856), plasma membrane (GO:0005886), endosome membrane (GO:0010008), cytoplasmic vesicle (GO:0031410), cell projection (GO:0042995)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
RHOBTB GTPase Cycle	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
actin cytoskeleton organization	2
cellular process	2
supramolecular fiber organization	1
cell communication	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
intracellular signaling cassette	1
regulation of cell morphogenesis	1
regulation of biological quality	1
cytoskeleton organization	1
regulation of actin filament-based process	1
regulation of cytoskeleton organization	1
ribonucleoside triphosphate phosphatase activity	1
guanyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
kinase binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
binding	1
intracellular membraneless organelle	1
membrane	1
cell periphery	1
endosome	1
cytoplasmic vesicle membrane	1
bounding membrane of organelle	1
cytoplasm	1
intracellular vesicle	1
cellular anatomical structure	1

Protein interactions and networks

STRING

2058 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
RHOBTB1	CUL3	Q13618	820
RHOBTB1	PLIN3	O60664	589
RHOBTB1	EGR2	P11161	505
RHOBTB1	RHOBTB3	O94955	411
RHOBTB1	RHOT2	Q8IXI1	395
RHOBTB1	SFTPC	P11686	388
RHOBTB1	TMT1B	Q6UX53	377
RHOBTB1	RHOT1	Q8IXI2	376
RHOBTB1	ARHGDIA	P52565	363
RHOBTB1	BTBD1	Q9H0C5	359
RHOBTB1	WNK4	Q96J92	358
RHOBTB1	BTBD3	Q9Y2F9	354
RHOBTB1	UBFD1	O14562	352
RHOBTB1	KLHL2	O95198	337
RHOBTB1	ARHGDIB	P52566	324

IntAct

52 interactions, top by confidence:

A	B	Type	Score
COPS6	RHOBTB1	psi-mi:“MI:0914”(association)	0.730
PRKN	RHOBTB1	psi-mi:“MI:0915”(physical association)	0.560
RHOBTB1	PRKCA	psi-mi:“MI:0915”(physical association)	0.560
RHOBTB1	YWHAG	psi-mi:“MI:0915”(physical association)	0.560
RHOBTB1	SETDB1	psi-mi:“MI:0915”(physical association)	0.560
RHOBTB1	KAT5	psi-mi:“MI:0915”(physical association)	0.560
LMO3	RHOBTB1	psi-mi:“MI:0915”(physical association)	0.560
CUL3	RHOBTB1	psi-mi:“MI:0914”(association)	0.530
APBB3	RHOBTB1	psi-mi:“MI:0914”(association)	0.530
PSG8	PEX7	psi-mi:“MI:0914”(association)	0.530
UBE2M	RHOBTB1	psi-mi:“MI:0914”(association)	0.530

BioGRID (462): Lrrc41 (Affinity Capture-Western), RHOBTB1 (Affinity Capture-MS), RHOBTB1 (Synthetic Lethality), RHOBTB1 (Affinity Capture-MS), RHOBTB1 (Affinity Capture-Western), RHOBTB1 (Affinity Capture-MS), BPIFA2 (Affinity Capture-MS), CST2 (Affinity Capture-MS), AMY1C (Affinity Capture-MS), CST1 (Affinity Capture-MS), RHOBTB1 (Affinity Capture-MS), RHOBTB1 (Affinity Capture-MS), IGHA2 (Affinity Capture-MS), RHOBTB1 (Affinity Capture-MS), CST4 (Affinity Capture-MS)

ESM2 similar proteins: A0JNA8, A2AFR3, A2AWP8, F1LXF1, O15034, O94844, O94967, O95267, P11274, P28028, Q01826, Q08BT5, Q14161, Q14CM0, Q15139, Q3UGM2, Q3UHE1, Q4R4I0, Q5R5M3, Q5VUG0, Q5XIS9, Q60611, Q62101, Q66H91, Q68FF6, Q6NZQ4, Q6PAJ1, Q6PB44, Q6ZW49, Q6ZWH5, Q80U28, Q8BWW9, Q8BZ03, Q8CGF6, Q8TCU6, Q8VDD9, Q8VI24, Q96GD3, Q9BZ71, Q9BZL6

Diamond homologs: A1L1L6, F4J0W4, O00212, O04369, O59781, O94844, P0CO78, P0CO79, P34144, P34150, P39722, P48554, P60763, P60764, Q17QI8, Q24814, Q298L5, Q2HJF8, Q2UM43, Q32LU1, Q35638, Q38912, Q38919, Q38937, Q39435, Q41253, Q41254, Q4I2W2, Q4PB75, Q4WN24, Q5B5L3, Q5E9M9, Q5ZM73, Q5ZM83, Q623S8, Q6C2J1, Q6CY37, Q6DIS1, Q6EP31, Q6FIR8

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
RHOBTB1	“down-regulates quantity by destabilization”	PDE5A	binding
RHOBTB1	“up-regulates activity”	“Cullin 3-RBX1-Skp1”	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 34 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
DNA Damage Recognition in GG-NER	6	74.5×	3e-08
Formation of TC-NER Pre-Incision Complex	6	55.2×	1e-07
Cargo recognition for clathrin-mediated endocytosis	6	27.3×	4e-06
Neddylation	8	16.5×	1e-06

GO biological processes:

GO term	Partners	Fold	FDR
regulation of protein neddylation	6	175.5×	1e-10
protein neddylation	6	131.7×	5e-10

Disease & clinical

Clinical variants and AI predictions

ClinVar

89 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	70
Likely benign	5
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2339 predictions. Top by Δscore:

Variant	Effect	Δscore
10:60871251:T:C	donor_gain	1.0000
10:60871476:T:TA	donor_gain	1.0000
10:60871647:GTTGT:G	acceptor_gain	1.0000
10:60871648:TTGT:T	acceptor_gain	1.0000
10:60871649:TGT:T	acceptor_gain	1.0000
10:60871652:C:A	acceptor_loss	1.0000
10:60871652:C:CC	acceptor_gain	1.0000
10:60871653:T:A	acceptor_loss	1.0000
10:60872291:C:CC	acceptor_gain	1.0000
10:60874205:AGTTT:A	donor_gain	1.0000
10:60874294:A:AC	donor_gain	1.0000
10:60874295:C:CC	donor_gain	1.0000
10:60874295:CA:C	donor_gain	1.0000
10:60874295:CACT:C	donor_gain	1.0000
10:60874950:AAAC:A	donor_loss	1.0000
10:60874951:AAC:A	donor_loss	1.0000
10:60874952:A:C	donor_loss	1.0000
10:60875038:CTGTT:C	acceptor_gain	1.0000
10:60875039:TGTT:T	acceptor_gain	1.0000
10:60875042:TCTG:T	acceptor_loss	1.0000
10:60875043:C:CC	acceptor_gain	1.0000
10:60875043:CTGGG:C	acceptor_loss	1.0000
10:60875044:T:G	acceptor_loss	1.0000
10:60877076:AACT:A	donor_gain	1.0000
10:60886111:CCTCA:C	donor_gain	1.0000
10:60886226:CACGT:C	acceptor_gain	1.0000
10:60886228:CGT:C	acceptor_gain	1.0000
10:60886229:GTC:G	acceptor_loss	1.0000
10:60886230:TCT:T	acceptor_loss	1.0000
10:60886231:C:A	acceptor_loss	1.0000

AlphaMissense

4613 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
10:60871610:A:G	W655R	1.000
10:60871610:A:T	W655R	1.000
10:60871622:A:G	W651R	1.000
10:60871622:A:T	W651R	1.000
10:60889045:A:G	L208P	1.000
10:60889054:C:G	R205P	1.000
10:60889101:G:C	S189R	1.000
10:60889101:G:T	S189R	1.000
10:60889103:T:G	S189R	1.000
10:60892859:G:T	R145S	1.000
10:60892861:A:G	L144P	1.000
10:60892872:G:C	C140W	1.000
10:60892876:C:T	G139E	1.000
10:60892877:C:A	G139W	1.000
10:60892877:C:G	G139R	1.000
10:60892877:C:T	G139R	1.000
10:60892926:C:A	W122C	1.000
10:60892926:C:G	W122C	1.000
10:60892928:A:G	W122R	1.000
10:60892928:A:T	W122R	1.000
10:60892974:A:C	C106W	1.000
10:60892975:C:T	C106Y	1.000
10:60892976:A:G	C106R	1.000
10:60892981:A:T	V104D	1.000
10:60892987:A:T	V102D	1.000
10:60892990:T:A	D101V	1.000
10:60892993:G:A	S100F	1.000
10:60910894:A:C	Y97D	1.000
10:60910894:A:G	Y97H	1.000
10:60910896:G:T	A96E	1.000

dbSNP variants (sampled 300 via entrez): RS1000007128 (10:60914072 G>C,T), RS1000011146 (10:60948545 C>T), RS1000014646 (10:60971632 T>C), RS1000046202 (10:60913582 C>T), RS1000059417 (10:60914371 C>T), RS1000061780 (10:60942155 T>C), RS1000070614 (10:60919765 C>T), RS1000073817 (10:60874473 C>T), RS1000074077 (10:60954473 A>G,T), RS1000119245 (10:60863318 T>A), RS1000125929 (10:60937151 G>A), RS1000136301 (10:60996686 C>T), RS1000141881 (10:60921243 T>C), RS1000157209 (10:60936907 C>T), RS1000162138 (10:60937808 T>C,G)

Disease associations

OMIM: gene MIM:607351 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

7 associations (top):

Study	Trait	p-value
GCST000394_2	Diastolic blood pressure	1.000000e-09
GCST002788_4	Milk allergy	5.000000e-06
GCST002790_4	Food allergy	7.000000e-06
GCST004766_13	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes	8.000000e-07
GCST008153_34	Lean body mass	7.000000e-06
GCST009391_1621	Metabolite levels	5.000000e-06
GCST012490_241	Femur bone mineral density x serum urate levels interaction	8.000000e-10

EFO canonical traits (7, from GWAS)

EFO ID	Trait name
EFO:0006336	diastolic blood pressure
EFO:0007019	milk allergy measurement
EFO:0007016	food allergy measurement
EFO:0007681	triglyceride change measurement
EFO:0004995	lean body mass
EFO:0010379	phosphatidylcholine 36:1 measurement
EFO:0004531	urate measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

68 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression, affects expression, increases methylation	8
Benzo(a)pyrene	decreases expression, increases mutagenesis, affects methylation	7
Estradiol	affects cotreatment, decreases expression, increases expression	5
Tetrachlorodibenzodioxin	affects cotreatment, decreases expression, increases expression	5
bisphenol A	increases methylation, increases expression, affects expression, affects cotreatment	4
Cyclosporine	decreases expression	4
Air Pollutants	decreases expression, affects cotreatment, increases abundance, increases oxidation	3
Particulate Matter	decreases expression, increases abundance, affects cotreatment, decreases abundance, increases expression	3
cobaltous chloride	decreases expression	2
epigallocatechin gallate	increases expression, affects cotreatment, decreases expression	2
FR900359	increases phosphorylation	1
triphenyl phosphate	affects expression	1
alpha-pinene	affects cotreatment, increases oxidation, increases abundance	1
2,5,2’,5’-tetrachlorobiphenyl	decreases expression	1
beta-lapachone	increases expression	1
afimoxifene	increases expression	1
sodium arsenite	decreases expression	1
butyraldehyde	decreases expression	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
nickel sulfate	decreases expression	1
muconaldehyde	decreases expression	1
methacrylaldehyde	increases abundance, affects cotreatment, increases oxidation	1
S-(1,2-dichlorovinyl)cysteine	increases expression, affects cotreatment, decreases expression, affects response to substance	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
abrine	decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	increases expression, increases response to substance	1
bisphenol S	decreases methylation	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.